{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1361699993483932160.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1002/hep.21698"}},{"identifier":{"@type":"URI","@value":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fhep.21698"}},{"identifier":{"@type":"URI","@value":"https://journals.lww.com/01515467-200707000-00031"}},{"identifier":{"@type":"PMID","@value":"17596850"}},{"identifier":{"@type":"HANDLE","@value":"2027.42/56065"}}],"dc:title":[{"@value":"Antiviral drug-resistant HBV"}],"dcterms:alternative":[{"@value":"Standardization of nomenclature and assays and recommendations for management"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:sec>\n            <jats:title>Abstract</jats:title>\n            <jats:p>\n                                 <jats:bold>Substantial advances have been made in the treatment of chronic hepatitis B in the past decade. Approved treatments for chronic hepatitis B include 2 formulations of interferon and 4 nucleos(t)ide analogues (NAs). Sustained viral suppression is rarely achieved after withdrawal of a 48-week course of NA therapy, necessitating long, and in many cases, indefinite treatment with increasing risk of development of drug resistance. Antiviral resistance and poor adherence are the most important factors in treatment failure of hepatitis B. Thus, there is a need to standardize nomenclature relating to hepatitis B antiviral resistance, and to define genotypic, phenotypic, and clinical resistance to NA therapy. (HEPATOLOGY 2007;46:254–265.)</jats:bold>\n                              </jats:p>\n          </jats:sec>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1381699993483932168","@type":"Researcher","foaf:name":[{"@value":"Anna S. Lok"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699993483932160","@type":"Researcher","foaf:name":[{"@value":"Fabien Zoulim"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699993483932167","@type":"Researcher","foaf:name":[{"@value":"Stephen Locarnini"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699993483932163","@type":"Researcher","foaf:name":[{"@value":"Angeline Bartholomeusz"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699993483932164","@type":"Researcher","foaf:name":[{"@value":"Marc G. Ghany"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699993483932162","@type":"Researcher","foaf:name":[{"@value":"Jean-Michel Pawlotsky"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699993483932166","@type":"Researcher","foaf:name":[{"@value":"Yun-Fan Liaw"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699993483932161","@type":"Researcher","foaf:name":[{"@value":"Masashi Mizokami"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699993483932165","@type":"Researcher","foaf:name":[{"@value":"Carla Kuiken"}]}],"contributor":[{"@id":"https://cir.nii.ac.jp/crid/1890303265840120082","@type":"Researcher","foaf:name":[{"@value":"Division of Gastroenterology, University of Michigan, Ann Arbor, MI"}]},{"@id":"https://cir.nii.ac.jp/crid/1890303265840120064","@type":"Researcher","foaf:name":[{"@value":"fax: 734-936-7392"}]},{"@id":"https://cir.nii.ac.jp/crid/1890303265840120065","@type":"Researcher","foaf:name":[{"@value":"Division of Gastroenterology, University of Michigan Health System, 3912 Taubman Center, Ann Arbor, MI 48109-0362"}]},{"@id":"https://cir.nii.ac.jp/crid/1890303265840120071","@type":"Researcher","foaf:name":[{"@value":"Victorian Infectious Diseases Reference Laboratory, North Melbourne, Victoria, Australia"}]},{"@id":"https://cir.nii.ac.jp/crid/1890303265840120077","@type":"Researcher","foaf:name":[{"@value":"Theoretical Biology and Biophysics Group (T-10), Los Alamos National Laboratory, Los Alamos, NM"}]},{"@id":"https://cir.nii.ac.jp/crid/1890303265840120070","@type":"Researcher","foaf:name":[{"@value":"Department of Clinical Molecular Informative Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1890303265840120074","@type":"Researcher","foaf:name":[{"@value":"Liver Diseases Branch, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD"}]},{"@id":"https://cir.nii.ac.jp/crid/1890303265840120073","@type":"Researcher","foaf:name":[{"@value":"INSERM, U271; UniversitÉ Lyon I; Hospices Civils de Lyon, Lyon, France"}]},{"@id":"https://cir.nii.ac.jp/crid/1890303265840120076","@type":"Researcher","foaf:name":[{"@value":"French National Reference Center for Viral Hepatitis B, C and delta, Department of Virology and INSERM U841, Hopital Henri Mondor, Universite Paris 12, Creteil, France"}]},{"@id":"https://cir.nii.ac.jp/crid/1890303265840120081","@type":"Researcher","foaf:name":[{"@value":"Liver Research Unit, Chang Gung University and Memorial Hospital, Taipei, Taiwan"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"02709139"}],"prism:publicationName":[{"@value":"Hepatology"}],"dc:publisher":[{"@value":"Ovid Technologies (Wolters Kluwer Health)"}],"prism:publicationDate":"2007-07","prism:volume":"46","prism:number":"1","prism:startingPage":"254","prism:endingPage":"265"},"reviewed":"false","dcterms:accessRights":"http://purl.org/coar/access_right/c_abf2","dc:rights":["http://doi.wiley.com/10.1002/tdm_license_1.1"],"url":[{"@id":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fhep.21698"},{"@id":"https://journals.lww.com/01515467-200707000-00031"}],"createdAt":"2007-06-27","modifiedAt":"2024-12-01","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=Clinical%20Trials%20as%20Topic","dc:title":"Clinical Trials as Topic"},{"@id":"https://cir.nii.ac.jp/all?q=Hepatitis%20B%20virus","dc:title":"Hepatitis B virus"},{"@id":"https://cir.nii.ac.jp/all?q=Hepatology","dc:title":"Hepatology"},{"@id":"https://cir.nii.ac.jp/all?q=Nucleotides","dc:title":"Nucleotides"},{"@id":"https://cir.nii.ac.jp/all?q=610","dc:title":"610"},{"@id":"https://cir.nii.ac.jp/all?q=Nucleosides","dc:title":"Nucleosides"},{"@id":"https://cir.nii.ac.jp/all?q=Hepatitis%20B","dc:title":"Hepatitis B"},{"@id":"https://cir.nii.ac.jp/all?q=Antiviral%20Agents","dc:title":"Antiviral Agents"},{"@id":"https://cir.nii.ac.jp/all?q=Life%20and%20Medical%20Sciences","dc:title":"Life and Medical Sciences"},{"@id":"https://cir.nii.ac.jp/all?q=Treatment%20Outcome","dc:title":"Treatment Outcome"},{"@id":"https://cir.nii.ac.jp/all?q=Terminology%20as%20Topic","dc:title":"Terminology as Topic"},{"@id":"https://cir.nii.ac.jp/all?q=Internal%20Medicine%20and%20Specialties","dc:title":"Internal Medicine and Specialties"},{"@id":"https://cir.nii.ac.jp/all?q=Health%20Sciences","dc:title":"Health Sciences"},{"@id":"https://cir.nii.ac.jp/all?q=Drug%20Resistance,%20Viral","dc:title":"Drug Resistance, Viral"},{"@id":"https://cir.nii.ac.jp/all?q=Humans","dc:title":"Humans"},{"@id":"https://cir.nii.ac.jp/all?q=Treatment%20Failure","dc:title":"Treatment Failure"}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1050282810708655104","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Dynamics of Hepatitis B Virus Quasispecies in Association with Nucleos(t)ide Analogue Treatment Determined by Ultra-Deep Sequencing."}]},{"@id":"https://cir.nii.ac.jp/crid/1050845763844328192","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Guidelines for avoiding risks resulting from discontinuation of nucleoside/nucleotide analogs in patients with chronic hepatitis B"},{"@value":"Guidelines for avoiding risks resulting from discontinuation of nucleoside/nucleotide analogs in patients with chronic hepatitis <scp>B</scp>"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004235757163264","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Management of hepatitis B: Consensus of the Japan Society of Hepatology 2009"}]},{"@id":"https://cir.nii.ac.jp/crid/1360025430216028928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Highlights from the 2023 International Meeting on the Molecular Biology of Hepatitis B virus"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565168116348928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"JSH Guidelines for the Management of Hepatitis B Virus Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567182238880768","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Effect of tenofovir disoproxil fumarate on drug-resistant HBV clones"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567182504089088","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Endoplasmic reticulum-mediated induction of interleukin-8 occurs by hepatitis B virus infection and contributes to suppression of interferon responsiveness in human hepatocytes"}]},{"@id":"https://cir.nii.ac.jp/crid/1360846640256640384","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848660687481088","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848664610468096","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"The Association between Serum Cytokine and Chemokine Levels and Antiviral Response by Entecavir Treatment in Chronic Hepatitis B Patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204792984064","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"日本肝臓学会コンセンサス神戸2009：C型肝炎の診断と治療"},{"@language":"en","@value":"JSH Consensus Kobe 2009: Diagnosis and Treatment of Hepatitis C"},{"@language":"ja-Kana","@value":"ニホン カンゾウ ガッカイ コンセンサス コウベ 2009 Cガタ カンエン ノ シンダン ト チリョウ"},{"@value":"日本肝臓学会コンセンサス神戸2009--B型肝炎の診断と治療"},{"@language":"ja-Kana","@value":"ニホン カンゾウ ガッカイ コンセンサス コウベ 2009 Bガタ カンエン ノ シンダン ト チリョウ"},{"@value":"JSH Consensus Kobe 2009: Diagnosis and Treatment of Hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204793861376","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Guidelines for avoiding risks resulting from discontinuation of nucleos(t)ide analogues in patients with chronic hepatitis B (2012)"},{"@language":"ja","@value":"核酸アナログ薬中止に伴うリスク回避のための指針2012―厚生労働省「B型肝炎の核酸アナログ薬治療における治療中止基準の作成と治療中止を目指したインターフェロン治療の有用性に関する研究」の報告―"},{"@language":"ja-Kana","@value":"カクサン アナログヤク チュウシ ニ トモナウ リスク カイヒ ノ タメ ノ シシン 2012 : コウセイ ロウドウショウ 「 Bガタ カンエン ノ カクサン アナログヤク チリョウ ニ オケル チリョウ チュウシ キジュン ノ サクセイ ト チリョウ チュウシ オ メザシタ インターフェロン チリョウ ノ ユウヨウセイ ニ カンスル ケンキュウ 」 ノ ホウコク"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679771619840","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Two cases of acute hepatitis due to hepatitis E virus that are indigenous to Kitakyushu: a case report"},{"@language":"ja","@value":"北九州に土着したE型肝炎ウイルス株による急性肝炎の2例"},{"@value":"B型肝炎治療ガイドライン(第1.1版)"},{"@language":"ja-Kana","@value":"Bガタ カンエン チリョウ ガイドライン(ダイ1.1ハン)"},{"@language":"ja-Kana","@value":"キタキュウシュウ ニ ドチャク シタ Eガタ カンエンウイルスカブ ニ ヨル キュウセイ カンエン ノ 2レイ"},{"@value":"Guidelines for the management of hepatitis B virus infection"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1002/hep.21698"},{"@type":"OPENAIRE","@value":"doi_dedup___::249dd23b400043721899a12484fd119e"},{"@type":"CROSSREF","@value":"10.1111/j.1872-034x.2010.00739.x_references_DOI_DFOeOnFQT890CNlZuak4mEqa07g"},{"@type":"CROSSREF","@value":"10.1099/jgv.0.001978_references_DOI_DFOeOnFQT890CNlZuak4mEqa07g"},{"@type":"CROSSREF","@value":"10.1111/hepr.12108_references_DOI_DFOeOnFQT890CNlZuak4mEqa07g"},{"@type":"CROSSREF","@value":"10.2957/kanzo.51.243_references_DOI_DFOeOnFQT890CNlZuak4mEqa07g"},{"@type":"CROSSREF","@value":"10.2957/kanzo.53.237_references_DOI_DFOeOnFQT890CNlZuak4mEqa07g"},{"@type":"CROSSREF","@value":"10.1111/hepr.12269_references_DOI_DFOeOnFQT890CNlZuak4mEqa07g"},{"@type":"CROSSREF","@value":"10.1371/journal.pone.0035052_references_DOI_DFOeOnFQT890CNlZuak4mEqa07g"},{"@type":"CROSSREF","@value":"10.1016/j.jinf.2015.09.038_references_DOI_DFOeOnFQT890CNlZuak4mEqa07g"},{"@type":"CROSSREF","@value":"10.1007/s00535-012-0737-2_references_DOI_DFOeOnFQT890CNlZuak4mEqa07g"},{"@type":"CROSSREF","@value":"10.1111/j.1872-034x.2011.00910.x_references_DOI_DFOeOnFQT890CNlZuak4mEqa07g"},{"@type":"CROSSREF","@value":"10.2957/kanzo.54.402_references_DOI_DFOeOnFQT890CNlZuak4mEqa07g"},{"@type":"CROSSREF","@value":"10.1016/j.virol.2018.08.020_references_DOI_DFOeOnFQT890CNlZuak4mEqa07g"},{"@type":"CROSSREF","@value":"10.3851/imp3196_references_DOI_DFOeOnFQT890CNlZuak4mEqa07g"}]}